智通财经获悉，TD Cowen预计，随着礼来 (LLY.US)和诺和诺德 (NVO.US)继续占据主导地位，到2030年，GLP-1类减重药物的全球销售额将达到1390亿美元，比之前的预测增长38%以上。该公司表示，礼来和诺和诺德继续占据主导地位，初级保健提供商对GLP-1的显著兴趣，以及竞争对手丰富的肥胖产品线，都是该公司调高预估的部分原因。
TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating ...
Oliver Chen, TD Cowen senior retail analyst, joins 'Money Movers' to discuss Wall Street's reaction to Walmart's quarterly ...
TD Cowen analyst Dan Brennan raised the firm’s price target on Guardant Health (GH) to $56 from $42 and keeps a Buy rating on the shares. The firm said results were inline with the preannouncement ...
Charles Schwab (NYSE:SCHW – Get Free Report) was upgraded by equities researchers at TD Cowen from a “hold” rating to a “buy” ...
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 45th Annual Health ...
TD Cowen analyst Jared Levine downgraded TriNet (TNET) to Hold from Buy with a price target of $74, down from $104, following the Q4 report.
TD Cowen raised the firm’s price target on Molson Coors (TAP) to $60 from $56 and keeps a Hold rating on the shares. The firm said they ...
TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...
周五，TD ...
today announced that the company will be participating in the upcoming TD Cowen 45th Annual Healthcare Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat ...
周五，TD Cowen重申对Booking Holdings（NASDAQ:BKNG）股票的买入评级，并将目标价从6,300.00美元上调至6,500.00美元。该公司分析师Kevin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback